Search

Your search keyword '"Larocca, Alessandra"' showing total 16 results
Start Over Author "Larocca, Alessandra" Publisher wiley
16 results on '"Larocca, Alessandra"'

2. Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Author

Larocca, Alessandra, primary, Leleu, Xavier, additional, Touzeau, Cyrille, additional, Bladé, Joan, additional, Paner, Agne, additional, Mateos, María‐Victoria, additional, Cavo, Michele, additional, Maisel, Christopher, additional, Alegre, Adrían, additional, Oriol, Albert, additional, Raptis, Anastasios, additional, Rodriguez‐Otero, Paula, additional, Mazumder, Amitabha, additional, Laubach, Jacob, additional, Nadeem, Omar, additional, Sandberg, Anna, additional, Orre, Marie, additional, Torrång, Anna, additional, Bakker, Nicolaas A., additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

3. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Author

Richardson, Paul G., primary, Schjesvold, Fredrik, additional, Weisel, Katja, additional, Moreau, Philippe, additional, Anderson, Larry D., additional, White, Darrell, additional, Rodriguez‐Otero, Paula, additional, Sonneveld, Pieter, additional, Engelhardt, Monika, additional, Jenner, Matthew, additional, Corso, Alessandro, additional, Dürig, Jan, additional, Pavic, Michel, additional, Salomo, Morten, additional, Beksac, Meral, additional, Oriol, Albert, additional, Lindsay, Jindriska, additional, Liberati, Anna Marina, additional, Galli, Monica, additional, Robak, Pawel, additional, Larocca, Alessandra, additional, Yagci, Munci, additional, Vural, Filiz, additional, Kanate, Abraham S., additional, Jiang, Ruiyun, additional, Grote, Lara, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios, additional

Published
2021
Full Text
View/download PDF

5. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate

Author

Milani, Paolo, primary, Fazio, Francesca, additional, Basset, Marco, additional, Berno, Tamara, additional, Larocca, Alessandra, additional, Foli, Andrea, additional, Riva, Marcello, additional, Benigna, Francesca, additional, Oliva, Stefania, additional, Nuvolone, Mario, additional, Rodigari, Lara, additional, Petrucci, Maria Teresa, additional, Merlini, Giampaolo, additional, and Palladini, Giovanni, additional

Published
2020
Full Text
View/download PDF

6. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Author

Gambella, Manuela, primary, Omedé, Paola, additional, Spada, Stefano, additional, Muccio, Vittorio Emanuele, additional, Gilestro, Milena, additional, Saraci, Elona, additional, Grammatico, Sara, additional, Larocca, Alessandra, additional, Conticello, Concetta, additional, Bernardini, Annalisa, additional, Gamberi, Barbara, additional, Troia, Rossella, additional, Liberati, Anna Marina, additional, Offidani, Massimo, additional, Rocci, Alberto, additional, Palumbo, Antonio, additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Oliva, Stefania, additional

Published
2018
Full Text
View/download PDF

8. Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials

Author

Gentile, Massimo, primary, Magarotto, Valeria, additional, Offidani, Massimo, additional, Musto, Pellegrino, additional, Bringhen, Sara, additional, Teresa Petrucci, Maria, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Uccello, Giuseppina, additional, Petrungaro, Annamaria, additional, Vigna, Ernesto, additional, Greco, Rosa, additional, Grazia Recchia, Anna, additional, Tripepi, Giovanni, additional, Ria, Roberto, additional, Di Raimondo, Francesco, additional, Palumbo, Antonio, additional, and Morabito, Fortunato, additional

Published
2017
Full Text
View/download PDF

10. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Author

Morabito, Fortunato, primary, Bringhen, Sara, additional, Larocca, Alessandra, additional, Wijermans, Pierre, additional, Victoria Mateos, Maria, additional, Gimsing, Peter, additional, Mazzone, Carla, additional, Gottardi, Daniela, additional, Omedè, Paola, additional, Zweegman, Sonja, additional, José Lahuerta, Juan, additional, Zambello, Renato, additional, Musto, Pellegrino, additional, Magarotto, Valeria, additional, Schaafsma, Martijn, additional, Oriol, Albert, additional, Juliusson, Gunnar, additional, Cerrato, Chiara, additional, Catalano, Lucio, additional, Gentile, Massimo, additional, Isabel Turel, Ana, additional, Marina Liberati, Anna, additional, Cavalli, Maide, additional, Rossi, Davide, additional, Passera, Roberto, additional, Rosso, Stefano, additional, Beksac, Meral, additional, Cavo, Michele, additional, Waage, Anders, additional, San Miguel, Jesus, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, Palumbo, Antonio, additional, and Offidani, Massimo, additional

Published
2014
Full Text
View/download PDF

11. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Author

Rocci, Alberto, primary, Gambella, Manuela, additional, Aschero, Simona, additional, Baldi, Ileana, additional, Trusolino, Livio, additional, Cavallo, Federica, additional, Gay, Francesca, additional, Larocca, Alessandra, additional, Magarotto, Valeria, additional, Omedè, Paola, additional, Isaia, Gianluca, additional, Bertotti, Andrea, additional, Liberati, Anna M., additional, Catalano, Lucio, additional, De Rosa, Luca, additional, Musto, Pellegrino, additional, Vallone, Roberto, additional, Falcone, Antonietta, additional, Drandi, Daniela, additional, Ladetto, Marco, additional, Comoglio, Paolo M., additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2014
Full Text
View/download PDF

12. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma

Author

Petrucci, Maria Teresa, primary, Levi, Anna, additional, Bringhen, Sara, additional, Scotti, Simona, additional, Gentilini, Fabiana, additional, Russo, Simone, additional, Siniscalchi, Agostina, additional, Larocca, Alessandra, additional, Grammatico, Sara, additional, Boccadoro, Mario, additional, Foà, Robin, additional, and Palumbo, Antonio, additional

Published
2012
Full Text
View/download PDF

13. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib‐containing regimens

Author

Benevolo, Giulia, primary, Larocca, Alessandra, additional, Gentile, Massimo, additional, Pregno, Patrizia, additional, Gay, Francesca, additional, Botto, Barbara, additional, Frairia, Chiara, additional, Evangelista, Andrea, additional, Morabito, Fortunato, additional, Boccadoro, Mario, additional, Vitolo, Umberto, additional, and Palumbo, Antonio, additional

Published
2010
Full Text
View/download PDF

14. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Author

Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, and Oliva S

Subjects
Clinical Trials, Phase III as Topic, Disease-Free Survival, Female, Flow Cytometry, Humans, Immunologic Factors therapeutic use, Lenalidomide therapeutic use, Male, Middle Aged, Neoplasm, Residual, Real-Time Polymerase Chain Reaction, Risk Factors, Treatment Outcome, Immunologic Factors administration & dosage, Lenalidomide administration & dosage, Maintenance Chemotherapy methods, Multiple Myeloma drug therapy
Abstract

Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis., Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10 -5 ) and MFC (sensitivity, from 10 -4 to 10 -5 )., Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P = .0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P < .001). The impact of negative MRD status on PFS was similar in all subgroups (ASCT and no-ASCT; International Staging System stages I, II, and III; high-risk and standard-risk cytogenetics), and the two techniques were highly correlated., Conclusions: MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results., (© 2018 American Cancer Society.)

Published
2019
Full Text
View/download PDF

15. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.

Author

Petrucci MT, Levi A, Bringhen S, Scotti S, Gentilini F, Russo S, Siniscalchi A, Larocca A, Grammatico S, Boccadoro M, Foà R, and Palumbo A

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Boronic Acids administration & dosage, Bortezomib, Disease-Free Survival, Female, Humans, Male, Maximum Tolerated Dose, Melphalan administration & dosage, Multiple Myeloma mortality, Prednisone administration & dosage, Pyrazines administration & dosage, Recurrence, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy
Abstract

Background: In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP) significantly increases the response rate and event-free survival compared with MP alone., Methods: In this phase 1/2 trial, the authors assessed the dosing, efficacy, and safety of a lower dose-intensity MP schedule plus weekly bortezomib as salvage treatment for elderly patients with MM. To assess the maximum tolerated dose, 19 patients who had relapsed/refractory MM after 1 or 2 lines of treatment entered the first phase of the study. They received melphalan at a dose of 24 mg for 28 days; bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22; and prednisone at a dose of 50 mg every other day of a 28-day cycle for a total of 9 cycles. At the end of the first phase, based on the good efficacy and acceptable toxicity of this combination, an additional 23 patients were enrolled., Results: After a median follow-up of 21 months, of 42 patients who relapsed, 24 (57%) obtained at least a partial response, 4 had stable disease, and 11 had progressive disease. The median time to progression was 18 months, and the median overall survival was 30 months. Grade 3 and 4 toxicity was observed in 16 of 42 patients (38%) and was more frequent during the early cycles., Conclusions: A weekly infusion of bortezomib associated with lower dose-intensity MP induced a high proportion of responses and was well tolerated in elderly patients with relapsed/refractory MM., (Copyright © 2012 American Cancer Society.)

Published
2013
Full Text
View/download PDF

16. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.

Author

Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, and Palumbo A

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bortezomib, Disease-Free Survival, Female, Humans, Male, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Boronic Acids administration & dosage, Dexamethasone administration & dosage, Multiple Myeloma drug therapy, Pyrazines administration & dosage
Abstract

Background: Although treatment for multiple myeloma (MM) has considerably improved in the past decade, MM continues to be an incurable hematological malignancy that causes most patients to eventually relapse and die from their illness. Thus, the identification of effective salvage strategies remains a priority., Methods: In this trial, the authors evaluated the safety and efficacy of bortezomib and dexamethasone [V: on days 1 and 15 (1.3 mg/mq); D: on days 1-2 and 15-16, every 28-day cycle until progression (20 mg/d)] as maintenance therapy (MT) in patients with advanced MM who responded to salvage therapy that used a bortezomib-containing regimen., Results: Forty-nine MM patients were enrolled in this study between October of 2004 and April of 2008. All patients who were included in this study were responsive to a prior salvage therapy with bortezomib and had a measurable disease. The bortezomib and dexamethasone MT improved the quality of responses to complete remission in 4 patients and very good partial response in 3 patients. In addition, 10 patients experienced at least a 50% improvement in their symptoms. The median time to progression (TTP) was 16 months with a progression-free survival of 61% after 1 year. The overall response after 1 year was 76%, and the cumulative incidence of death due to disease progression, which was adjusted for competitive risk events, was 14%. Non-dose-limiting toxicities included neuropathy (predominantly grade 1), herpes zoster reactivation, pneumonia, and gastrointestinal affections (constipation and diarrhea). Three patients developed grade 2 neuropathy, which required a bortezomib dose reduction to 1.0 mg/mq. No grade 3 or 4 toxicities were recorded., Conclusions: The use of bortezomib and dexamethasone as MT in advanced MM was effective and well tolerated. The twice-monthly bortezomib infusion appeared to reduce the incidence of grade 3 and 4 neuropathies in comparison to similar experiences in other settings., (Copyright © 2010 American Cancer Society.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results